• $26.8M
    Market Cap
  • N/A
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: N/A
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

NLS Pharmaceutics and Kadimastem have been granted a Hong Kong patent for cell-selection technology used in IsletRx, a stem cell-derived therapy for insulin-dependent diabetes, expanding their intellectual property protection in Asia.

09/04/2025, 7:38 AM • Benzinga

Peers

  • SABS
    SAB BIOTHERAP
    $3.90+4.56%
    Market Cap$285.2M
    1-Year Change+38.66%
  • SRZN
    SURROZEN
    $23.10+1.27%
    Market Cap$264.8M
    1-Year Change+164.92%
  • CELU
    CELULARITY-A
    $0.77+2.50%
    Market Cap$21.9M
    1-Year Change-66.29%
  • KTTA
    PASITHEA THERAP
    $0.490.00%
    Market Cap$16.4M
    1-Year Change-28.99%
  • NUWE
    Nuwellis
    $2.82+0.71%
    Market Cap$1.0M
    1-Year Change-98.98%
  • PRE
    PRENETICS GLB
    $18.680.00%
    Market CapN/A
    1-Year Change+132.05%
  • CERO
    Cero Therap
    $0.07+403.36%
    Market CapN/A
    1-Year Change-99.83%

Statistics

More
Day Range
$3.92
$4.32
$4.00
1-Year Range
$1.88
$7.29
$4.00
Latest Close$4.00
Change
-$0.19 (-4.75%)
Volume20,683
Market Cap$26.8M
Shares Outstanding6.7M
P/E (TTM)1.85
Diluted EPS (TTM)$2.16
Enterprise Value$30.7M

Information as of 07/13/2026

Company Profile

NEWCELX LTD
https://newcelx.com
$26.8M
Market Cap
-$8.3M
Net Income
Sector: Healthcare
Industry: Biotechnology
Hohstrasse 1, Kloten, Switzerland, 8302
41 44 512 21 50

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.

Key Executives

  • Yossi Ben-Yossef
  • Alexander Zwyer
  • Ronen Twito
  • Eric Konofal
  • Omri Hagai

Current Ownership Distribution

  • Insiders1.3M (99.94%)
  • Institutions835 (0.06%)
  • Mutual Funds0 (0.00%)
  • Other0 (0.00%)